Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Patent
1998-04-30
1999-05-04
Brouillette, D. Gabrielle
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
514946, 424449, A61F 1302
Patent
active
059002506
ABSTRACT:
A composition of matter for application to a body surface or membrane to administer oxybutynin by permeation through the body surface or membrane, the composition comprising, in combination, the oxybutynin to be administered, in a therapeutically effective amount; and a permeation-enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactic ester or a mixture of lactate esters; present in specific concentrations.
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3527864 (1970-09-01), MacMillan et al.
patent: 3551554 (1970-12-01), Herschler
patent: 3598122 (1971-08-01), Zaffaroni
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3731683 (1973-05-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 3896238 (1975-07-01), Smith
patent: 3903256 (1975-09-01), MacMillan et al.
patent: 3952099 (1976-04-01), Smith
patent: 3987052 (1976-10-01), Hester
patent: 4006218 (1977-02-01), Sipos
patent: 4031894 (1977-06-01), Urquhart et al.
patent: 4046886 (1977-09-01), Smith
patent: 4116956 (1978-09-01), Meguro
patent: 4130643 (1978-12-01), Smith
patent: 4130667 (1978-12-01), Smith
patent: 4144317 (1979-03-01), Higuchi et al.
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4286592 (1981-09-01), Chandrasekaran
patent: 4299826 (1981-11-01), Luedders
patent: 4314557 (1982-02-01), Chandrasekaran
patent: 4335115 (1982-06-01), Thompson et al.
patent: 4343798 (1982-08-01), Fawzi
patent: 4379454 (1983-04-01), Campbell et al.
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4435180 (1984-03-01), Leeper
patent: 4440777 (1984-04-01), Zupan
patent: 4464378 (1984-08-01), Hussain
patent: 4468391 (1984-08-01), Voith
patent: 4474845 (1984-10-01), Korol
patent: 4508726 (1985-04-01), Coleman
patent: 4537776 (1985-08-01), Cooper
patent: 4552872 (1985-11-01), Cooper et al.
patent: 4557934 (1985-12-01), Cooper
patent: 4559222 (1985-12-01), Enscore et al.
patent: 4568343 (1986-02-01), Leeper et al.
patent: 4573995 (1986-03-01), Cheng
patent: 4588580 (1986-05-01), Gale et al.
patent: 4588721 (1986-05-01), Mahan
patent: 4588739 (1986-05-01), Glassman
patent: 4590190 (1986-05-01), Saito et al.
patent: 4595684 (1986-06-01), Bennett
patent: 4626539 (1986-12-01), Aungst et al.
patent: 4634703 (1987-01-01), Kurtz et al.
patent: 4645502 (1987-02-01), Gale et al.
patent: 4663454 (1987-05-01), Huber
patent: 4666903 (1987-05-01), Gallager
patent: 4683231 (1987-07-01), Glassman
patent: 4685913 (1987-08-01), Amidon et al.
patent: 4704282 (1987-11-01), Campbell et al.
patent: 4710497 (1987-12-01), Heller et al.
patent: 4721709 (1988-01-01), Seth et al.
patent: 4746515 (1988-05-01), Cheng et al.
patent: 4752612 (1988-06-01), Saito et al.
patent: 4783450 (1988-11-01), Fawzi et al.
patent: 4783456 (1988-11-01), Glassman
patent: 4784857 (1988-11-01), Berry et al.
patent: 4788062 (1988-11-01), Gale et al.
patent: 4795644 (1989-01-01), Zentner
patent: 4801458 (1989-01-01), Hidaka
patent: 4806341 (1989-02-01), Chien
patent: 4814183 (1989-03-01), Zentner
patent: 4816258 (1989-03-01), Nedberge et al.
patent: 4820720 (1989-04-01), Sanders et al.
patent: 4849224 (1989-07-01), Chang
patent: 4849226 (1989-07-01), Gale
patent: 4851228 (1989-07-01), Zentner et al.
patent: 4863720 (1989-09-01), Burghart et al.
patent: 4863738 (1989-09-01), Taskovich
patent: 4863970 (1989-09-01), Patel et al.
patent: 4865848 (1989-09-01), Cheng et al.
patent: 4908027 (1990-03-01), Enscore et al.
patent: 4908389 (1990-03-01), Mahjour et al.
patent: 4913905 (1990-04-01), Frankhauser
patent: 4925844 (1990-05-01), Resch
patent: 4928680 (1990-05-01), Sandbarik
patent: 4933184 (1990-06-01), Tauk
patent: 4935428 (1990-06-01), Lewis
patent: 4940586 (1990-07-01), Cheng et al.
patent: 4943435 (1990-07-01), Baker
patent: 4968507 (1990-11-01), Zentner et al.
patent: 4981468 (1991-01-01), Benefiel
patent: 4992445 (1991-02-01), Lawter et al.
patent: 4994278 (1991-02-01), Sablotsky et al.
patent: 5004610 (1991-04-01), Osborne et al.
patent: 5017575 (1991-05-01), Golwyn et al.
patent: 5030629 (1991-07-01), Rajadhyaksha
patent: 5041437 (1991-08-01), Yoshida et al.
patent: 5059427 (1991-10-01), Yoshida et al.
patent: 5071656 (1991-12-01), Lee
patent: 5108995 (1992-04-01), Casper
patent: 5122382 (1992-06-01), Gale
patent: 5122383 (1992-06-01), Heiber et al.
patent: 5149538 (1992-09-01), Granger
patent: 5198223 (1993-03-01), Gale
patent: 5211952 (1993-05-01), Spicer et al.
patent: 5246949 (1993-09-01), Yoshida et al.
patent: 5252588 (1993-10-01), Azuma et al.
patent: 5256421 (1993-10-01), Casper
patent: 5276022 (1994-01-01), Casper
patent: 5314694 (1994-05-01), Gale
patent: 5411740 (1995-05-01), Lee et al.
Keshary et al., "Development of Transdermal Delivery Systems for Oxybutynin In-Vivo Bioavailability" Pharm. Res., (NY) 8 (10 Suppl.) 1991, p. 5205.
1992 Physicians Desk Reference, pp. 1332-1333.
Idson, "Percutanoaus Absorption," J. Pharm. Sci., vol. 64, No. 66, Jun. 1975 pp. 901-924.
Abstract of Japanese Patent No. JP 04273818-A, dated Feb. 28, 1991.
Abstract of Japanese No. JP04099719 dated Mar. 31, 1992.
Abstract of Japanese Patent No. JP 04266821 dated Sep. 22, 1992.
Tetrahedron Letters No. 20, pp. 1609-1612. Pergammon Press (1971). Hester, Jackson B., Duchamp, David J. Chidester, A Synthetic Approach to New 1,4-Benzodiazepine Dervatives.
J. of Med. Chem., 1977, V. 20, p. 1694, Walser, Armin and Zenchoff, Gladys, "Quinazolines and 1,4-Benzodiazepines. 81.' Hydrazones".
Current Ther. Res. Jun. 1976, V. 19, pp. 661-668, Nakajima; Take; Moriya; Saji; Yui; nagawa, Pharmacological Studies on New Potent Central Depressants; 8-Chloro-6-Phenyl-4H-s-Triazlo.
Naunyn-Schmiedeberg's Arch. Pharmacol. 301, pp. 157-161 (1978), Sethy, Vimala H. Sethy, "Effect of Hypnotic and Anxiolytic Agents on regional Concentration of Acetylcholine in Rat Brain".
Current Therapeutic Res., V. 19, No. 6, Jun. 1976, pp. 661-668, Fabre, Louis F., Jr., Pilot Open Label Study with Alprozolam (U31;889) in Outpatients with Neurotic Depression Alprozolam (U31;899) in outpatients with Neurotic Depression.
J. Clin. Psychiatry 42:9, Sep. 1981 pp. 347-351, Cohn, Jay B., "Multicenter Double-Blind Efficacy and Safety Study Comparing Alprazolam, Diazepam and Placebo in Clinically Anxious Patients".
J. Clin. Psychiatry, 44, 45 (1983) pp. 45-47, Abernethy, Greenlatt, Divol and Shader, "Pharmacokinetics of Alprazolam".
Pharmacotherapy, 2, (1982), pp. 243-254, Fawcett and Kravitz, "Alprozolam: Pharmacokinetics, Clinical Efficacy, and Mechanism of Action".
CRC Critical Review and Therapeutic Drug Carrier Systems, vol. 4, Issue 1 (1987) pp. 13-37 Knepp, Hadgraft, Guy, "Transdermal Drug Delivery: Problems and Possibilities".
J. of Pharmaceutical Sciences, V. 64, No. 6, Jun. 1975, pp. 901-924, Idson, "Percutaneous Absorption".
J. of Pharmacology & Experimental Therapeutics, 1992 V. 256, No. 2, pp. 562-567, Noronha-Blob and Kachur, Enantiomers Oxybutynin: In Vitro Pharmacological Characterization at M.sub.1, M.sub.2, M.sub.3 Muscarinic etc.
J. of Pharmacology & Experimental Therapeutics, 1991 V. 247, No. 3, pp. 867-872, Kachur et al., "R & S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder & Intestine".
Burkoth Terry L.
Gale Robert M.
Lee Eun Soo
Watanabe Tyler
ALZA Corporation
Brouillette D. Gabrielle
Rafa Michael J.
Sabatine Paul
Stone Steven F.
LandOfFree
Monoglyceride/lactate ester permeation enhancer for oxybutnin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoglyceride/lactate ester permeation enhancer for oxybutnin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoglyceride/lactate ester permeation enhancer for oxybutnin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1868651